Term
|
Definition
| alkylating agents, epipodophyllotoxins |
|
|
Term
| AE: acrolein causes hemorrhagic cystitis |
|
Definition
|
|
Term
| alkylating agent used for multiple myeloma |
|
Definition
|
|
Term
|
Definition
|
|
Term
| MOA: alkylating agent, activated spontaneously |
|
Definition
|
|
Term
| MOA: purine analog and alkylating agent |
|
Definition
| bendamustine; tx: follicular lymphoma |
|
|
Term
| MOA: intercalating agent; tx: germ cell tumors |
|
Definition
|
|
Term
| AE: emesis, nephrotoxicity, ototoxicity, irreversible neurotoxicity, myelosuppression, acute and late hematogenicity |
|
Definition
|
|
Term
| MOA: inhibits dihydrofolate reductase |
|
Definition
|
|
Term
| MOA: requires polyglutamation for activation |
|
Definition
|
|
Term
| rescues cells from methotrexate |
|
Definition
|
|
Term
| administered with bicarbonate bc of nephrotoxicity AE |
|
Definition
|
|
Term
| administered with folate and B12 to reduce fatigue; tx: malignant mesothelioma |
|
Definition
|
|
Term
| MOA: inhibits thymidylate synthase, incorporated into RNA |
|
Definition
|
|
Term
|
Definition
|
|
Term
| AE: diarrhea, hand-foot syndrome |
|
Definition
| 5-fluorouracil, capaceitabine |
|
|
Term
|
Definition
|
|
Term
| activated by thymidine phosphorylase found in tumor cells; administered orally |
|
Definition
|
|
Term
| inhibits DNA polymerases alpha, beta, and gamma; DNA chain terminator |
|
Definition
|
|
Term
|
Definition
|
|
Term
| MOA: purine analog, inhibits CD4 and CD8 T cells |
|
Definition
|
|
Term
| AE: increases risk for opportunistic infections, autoimmune hemolytic anemia |
|
Definition
|
|
Term
| inhibits 5-alpha reductase in conversion of testosterone to dihydrotestosterone |
|
Definition
|
|
Term
|
Definition
| cisplatin, vincristine/vinblastine/vinorelbine, thalidomide/lenalidomide, bortezomib |
|
|
Term
| tx for hairy cell leukemia |
|
Definition
|
|
Term
| MOA: inhibits ribonucleotide reductase, reduces dNTP pools; tx for CML, polycythemia vera, essential thrombocytosis |
|
Definition
|
|
Term
| MOA: inhibits polymerization of tubulin |
|
Definition
| vincristine, vinblastine, vinorelbine |
|
|
Term
| MOA: inhibits depolymerization of tubulin |
|
Definition
|
|
Term
| exerts effects in M phase |
|
Definition
|
|
Term
|
Definition
| trastuzumab, daunorubicin/doxorubicin/epirubicin, arsenic trioxide |
|
|
Term
| AE: hypersensitivity reaction due to cremaphore |
|
Definition
|
|
Term
| anthracycline antibiotics; AE: cardiotoxicity |
|
Definition
| daunorubicin, doxorubicin, epirubicin |
|
|
Term
| forms ssDNA and dsDNA breaks, inhibits DNA replication, causes free radical formation, inhibits topoisomerase II |
|
Definition
| daunorubicin, doxorubicin, epirubicin |
|
|
Term
| inhibits topoisomerase II, causes G2 arrest |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| AE: myelosuppression, nausea, acute leukemia |
|
Definition
|
|
Term
|
Definition
| rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone |
|
|
Term
| combination tx for breast cancer |
|
Definition
| doxorubicin+cyclophosphamide, paclitaxel |
|
|
Term
| combination tx for testicular cancer |
|
Definition
| bleomycin, etoposide, cisplatin |
|
|
Term
| tx for anticipatory emesis |
|
Definition
| benzodiazepines, diazepam |
|
|
Term
| inhibits chemotherapy induced nausea and emesis |
|
Definition
| dolasetron, granisetron, ondansetron, palonosetron |
|
|
Term
| AE: impotence, lack of libido |
|
Definition
|
|
Term
|
Definition
|
|
Term
| MOA: competitive inhibitor of androgen receptors |
|
Definition
| flutamide, biclutamide, nilutamide |
|
|
Term
| AE: hot flashes, gynecomastia |
|
Definition
| flutamide, biclutamide, nilutamide |
|
|
Term
| inhibits osteoporosis, decreases total cholesterol; requires CYP2D6 activation, prevents BC, increases cure rate after surgery, inhibits metastasis of BC |
|
Definition
|
|
Term
| AE: hot flashes, thromboembolic phenomena |
|
Definition
|
|
Term
| indicated for post-menopausal females only |
|
Definition
| aromatase inhibitors: anastrozole |
|
|
Term
| AE: arthralgia, myalgia, osteoporosis |
|
Definition
| aromatase inhibitors: anastrozole |
|
|
Term
| inhibits adrenal steroid synthesis and ER levels; AE: weight gain |
|
Definition
| medroxyprogesterone, megestrol |
|
|
Term
| somatostatin analogue; inhibits GI hormone production; tx for carcinoid syndromes and chemotherapy-induced diarrhea |
|
Definition
|
|
Term
|
Definition
|
|
Term
| humanized anti-CD52 ab; tx: CLL |
|
Definition
|
|
Term
| AE: opportunistic infections |
|
Definition
|
|
Term
|
Definition
|
|
Term
| AE: reduced left ventricular ejection fraction |
|
Definition
|
|
Term
| anti-EGFR IgG1 chimeric monoclonal ab |
|
Definition
|
|
Term
| anti-EGFR humanized IgG2 ab |
|
Definition
|
|
Term
| AE: acneiform rash, surrogate measure of response to tx |
|
Definition
| anti-EGFR mabs: cetuximab, panitumumab |
|
|
Term
| anti-VEGF recombinant humanized mab; long half life |
|
Definition
|
|
Term
| AE: hypertension, proteinuria, CHF, poor wound healing, hemorrhage, GI perforation |
|
Definition
|
|
Term
| radioimmunoconjugates that target CD20; AE: radiation-related myelosuppression |
|
Definition
| ytrium+ibritumomab tiuxetan; and iodine+tositumomab |
|
|
Term
| anti-CD33 humanized mab conjugated to calicheamicin |
|
Definition
|
|
Term
| mab-cytotoxic conjugate; causes dsDNA breaks; tx for CD33+ AML in first relapse |
|
Definition
|
|
Term
| tx for BCR-ABL CML; AE: neutropenia, thrombocytopenia |
|
Definition
| imatinib, dasatinib, nilotinib |
|
|
Term
| intracellular her1/EGFR/Tyr kinase inhibitor |
|
Definition
|
|
Term
| intracellular her2/Tyr kinase inhibitor |
|
Definition
|
|
Term
| multi-RTK inhibitors; tx for liver and kidney cancers |
|
Definition
|
|
Term
| immunomodulatory; tx for multiple myeloma and MDS |
|
Definition
| thalidomide, lenalidomide |
|
|
Term
| AE: peripheral neuropathy, DVT |
|
Definition
| thalidomide, lenalidomide |
|
|
Term
|
Definition
|
|
Term
| downregulates NF-kB, induces apoptosis |
|
Definition
| proteosome inhibitor: bortezomib |
|
|
Term
|
Definition
| melphalan, thalidomide/lenalidomide, bortezomib |
|
|
Term
| promotes apoptosis, upregulates p53 and caspases |
|
Definition
|
|
Term
| AE: prolongs cardiac QT interval |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| topoisomerase II inhibitors, vinca alkaloids |
|
|
Term
|
Definition
| vincristine, asparaginase, glucocorticoids |
|
|
Term
| tx for refractory or relapsed indolent NHL |
|
Definition
|
|
Term
|
Definition
| R-CHOP (rituximab, vincristine, doxorubicin, prednisone) |
|
|
Term
| tx for Hodgkin's lymphoma |
|
Definition
| ABVD: alkylating agent, bleomycin, vincristine, doxorubicin |
|
|
Term
|
Definition
|
|
Term
| tx for first AML CD33+ relapse |
|
Definition
| gemtuzumab ozogamicin (antiCD33) |
|
|
Term
|
Definition
| bortezomib, thalidomide/lenalidomide |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| tx for CMML with PDGFR translocation |
|
Definition
|
|
